TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02634359

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Test
Description: Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Test
Description: Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
Study: NCT03769207

Intervention type: DEVICE
Group type: OTHER
Intervention: Ambulatory ECG
Description: Eligible participants are asked to wear the ambulatory ECG monitor
Study: NCT03526783

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux en Y gastric bypass
Description: Laparoscopic Roux en Y gastric bypass (150 cm alimentary limb, 50 cm biliopancreaty limb)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mini/One anastomosis gastric bypass
Description: Laparoscopic Mini/One anastomosis gastric bypass (200 cm biliopancreatic limb)
Study: NCT01043224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle
Description: Once daily application
Study: NCT00306930

Intervention type: DEVICE
Group type: OTHER
Intervention: Acetabular cup
Description: Acetabular cup replacement
Study: NCT03295383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab 1g IV
Description: Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 50Mg Oral Tablet
Description: cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Rituximab
Description: Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
Study: NCT01261091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Tracheostomy
Description: Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late Tracheostomy
Description: Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
Study: NCT00590512

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High sodium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low sodium
Study: NCT03164538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology + Motivational Interviewing
Description: Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
Study: NCT03810326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTR device (tradename named Xtend)
Description: Non invasive active splint
Study: NCT03295383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: cyclophosphamide placebo will be administered orally once daily
Study: NCT01684709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemonitoring + self-management support
Description: Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
Study: NCT03505723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative hypotension-avoidance strategy
Description: Perioperative hypotension-avoidance strategy includes:~1. Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~2. Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~3. Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Perioperative hypertension-avoidance strategy
Description: Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
Study: NCT02747589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical device implant in brain
Description: Neuropace RNS implant ove visual cortex
Study: NCT00244933

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine IV-1000mg/m2: Days 1 \& 8 every 21 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Biopsy of tumor prior to dose of genistein (Novasoy)
Study: NCT00070317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo complete pelvic and low para-aortic lymphadenectomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sulfur Colloid
Description: Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
Study: NCT00266214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch 5%
Description: 1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine patch 5%
Description: 1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
Study: NCT00070317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo radical hysterectomy
Study: NCT02189759

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Kangaroo Mother Care to one hour after birth
Description: Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
Study: NCT03403361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siemens Somatom Definition Edge
Description: In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Brilliance Big Bore CT/simulator
Description: In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study.
Study: NCT02604654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqitongluo granule
Description: administered after dissolved
Study: NCT00107315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT00527683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin
Description: crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orange juice is administered twice daily in containers indistinguishable from the treatment arm.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group therapy
Description: Participants attend group sessions once a week

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Group therapy
Description: Participants attend group sessions once a week
Study: NCT01761591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with Svelte Acrobat
Description: Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with other BMS
Description: Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
Study: NCT02890953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumostem
Description: direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: direct intracerebroventricular injection of normal saline via ventricular tap
Study: NCT03822455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OligoG DPI
Description: OligoG Dry Powder for Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OligoG DPI
Description: OligoG Dry Powder for Inhalation
Study: NCT03061721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 1 mg
Description: Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 2 mg
Description: Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar magnesium 4 mg
Description: Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
Study: NCT04489147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 850 mg orally twice daily along the cycle of ICSI
Study: NCT01431014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasonelow-dose
Description: 5mg
Study: NCT02189759

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Kangaroo Mother Care to one hour after birth
Description: Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Kangaroo Mother Care to discharge
Description: Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (\>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
Study: NCT01431014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasonehigh-dose
Description: 15 mg
Study: NCT01129713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretol
Description: Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
Study: NCT00518648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention program
Description: Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study: NCT00642434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Description: variable

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: variable
Study: NCT03315897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: 40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
Study: NCT01703208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to omarigliptin capsule or tablet administered orally once weekly
Study: NCT02060630

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open surgical revascularization

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open surgical revascularization

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular revascularization
Description: A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.

Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular revascularization
Description: A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
Study: NCT03898466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Inhaled corticosteroid

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Placebo inhaler
Study: NCT03213782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature based sounds
Description: Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
Study: NCT00096226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Carboplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Paclitaxel
Study: NCT01880749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study: NCT04816136

Intervention type: OTHER
Intervention: Sleep recording (already done)
Description: Sleep recording (already done)
Study: NCT04585230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: CBD oil Roll-On Stick

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: CBD oil Roll-On Stick

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Oil
Description: Mineral Oil- Roll on Stick

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Oil
Description: Mineral Oil- Roll on Stick

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Roll- On stick with no CBD and no Mineral Oil
Study: NCT03207737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MENTOR + Telehealth
Description: Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth Only
Description: Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
Study: NCT03387007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support training for school teachers
Description: The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
Study: NCT00349921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Clonidine-a drug commonly used to treat high blood pressure-has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: Adenosine-a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms-has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive substance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive substance
Study: NCT04171791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199 (venetoclax)
Description: Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
Study: NCT02493257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01183052

Intervention type: OTHER
Group type: OTHER
Intervention: Training
Description: 20 sessions of training
Study: NCT04161443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: * Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: * Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~* The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention).
Study: NCT00809991

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionation
Description: 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T